)
Edge31 Oct 2025
Rolls-Royce: Full Thrust Ahead
From century-old crafted perfection to pandemic shock and reset, Rolls-Royce's story is shaped by heritage, turbulence, and a disciplined climb back.
Chugai Pharmaceutical Co (4519) investor relations material
Chugai Pharmaceutical Co Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary24 Oct, 2025
Executive summary
Revenue and profit increased year-over-year, with Q3 FY2025 revenue at ¥911.6 billion (+5.0%) and core operating profit at ¥450.5 billion (+5.6%), driven by robust domestic and overseas sales, especially from Hemlibra, Actemra, Phesgo, PiaSky, Vabysmo, and Enspryng.
Overseas sales saw major growth, particularly from Actemra exports to Roche, while domestic performance was strong for both new and mainstay products.
Strategic acquisition of Renalys Pharma (Rhenalis/Renalys) secured sparsentan for the nephrology pipeline, with plans for domestic filing in 2026.
The company remains on track to meet or exceed full-year targets, supported by steady progress in core products, successful new launches, and pipeline advances.
Continued investment in manufacturing, R&D, and external partnerships, including Rani Therapeutics collaboration and plant expansions.
Financial highlights
Q3 revenue was ¥911.6 billion (+5.0% year-over-year); core operating profit was ¥450.5 billion (+5.6%); net income was ¥320.0 billion (+6.2%).
Domestic sales reached ¥343.7 billion (+3.6%), and overseas sales rose to ¥450.9 billion (+7.7%).
Operating margin improved to 49.4% (up 0.3 points year-over-year); net income margin was 35.1%.
Cost to sales ratio increased to 33.1% (up 0.6 points), with cost of goods sold at ¥263 billion (+7.9%).
Net cash decreased by ¥113.9 billion to ¥882.4 billion, mainly due to tax and dividend payments.
Outlook and guidance
Full-year revenue forecast is ¥1,190.0 billion (+1.7%), with core operating profit of ¥570.0 billion (+2.5%) and core net income of ¥410.0 billion (+3.2%).
75–76.6% of annual sales and profit targets were achieved by the end of Q3, with Q4 sales expected to be higher due to shipment timing and seasonality.
Overseas sales are expected to exceed forecasts, driven by Hemlibra and Actemra exports, while Actemra biosimilar erosion remains a risk.
Dividend payout will return to the regular policy after a special 100th anniversary dividend this year.
No changes have been made to previously announced forecasts.
R&D pipeline strategy after discontinuations?
Renalys Pharma acquisition's strategic rationale?
Reliance on Roche for overseas sales growth?
How does sparsentan acquisition fit strategy?
Orforglipron: When to expect budget inclusion?
Explain pipeline readout timing changes
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Chugai Pharmaceutical Co earnings date
Investor Day 202527 Nov, 2025
Next Chugai Pharmaceutical Co earnings date
Investor Day 202527 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Chugai Pharmaceutical Co., Ltd., operating under the umbrella of F. Hoffmann-La Roche Ltd, is a notable player in the pharmaceutical industry, mainly in Japan. Chugai is dedicated to the research, development, commercialization, and manufacture of biopharmaceuticals and therapeutic antibodies. The company's product range focuses on several therapeutic areas such as cancer, bone and joint diseases, renal diseases, and immune disorders, among others. It also plays a significant role in the global healthcare market through its international operations in North America, Europe, and other regions in Asia. Chugai Pharmaceutical is headquartered in Tokyo, Japan, and its shares are listed on the Tokyo Stock Exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage